Analysis: Maria Elvira Salazar's buy of MRNA (Moderna, Inc.)

Assessment: Low signal

Rep. Salazar's same-day buy and sell of MRNA represents a likely administrative or broker error with zero signal value.

• Member: Maria Elvira Salazar
• Party / state: R-FL
• Chamber: House
• Transaction: Buy
• Amount: $1,001 - $15,000
• Ticker: MRNA
• Company: Moderna, Inc.
• Trade date: 2026-08-19
• Disclosure date: 2026-09-09
• Disclosure lag: 21 days

Executive summary

This research package documents primary-source context for Rep. Maria Elvira Salazar’s 2026-08-19 purchase of Moderna (MRNA) and related activity. Public records collected include: (1) Moderna’s SEC 10-K filed 2026-02-20; (2) Federal Register notices including an FDA VRBPAC meeting/public docket for Moderna’s influenza vaccine (MFLUSIVA) published 2026-05-22; and (3) USAspending.gov contract/IDV records showing HHS activity for pediatric COVID vaccines including a funding action dated 2026-08-21, shortly after the trade date.

Within the 365 days prior to the trade date, Federal Register publications included an FDA notice (91 FR 30309, published 2026-05-22) announcing a VRBPAC meeting and public docket specifically for “Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) … manufactured by Moderna TX Inc.”, with the meeting stated as 2026-06-18. Around the trade window, USAspending.gov shows an HHS IDV award page for “FY26-27 PEDIATRIC COVID VACCINES EO 14398” with a listed funding-only action dated 2026-08-21 for $82,821,809. The member’s provided trading history shows two MRNA transactions, both dated 2026-08-19 (a purchase and a same-day sale at the same listed price in the user-provided dataset), and additional same-day trades in CB (sale), MRK (purchase), and QCOM (sale). Due to tool result limits, additional mandatory searches (Congress.gov keyword searches, Federal Register agency-filtered searches, and broader news retrieval) could not be completed in this run.

Timeline

• 2026-05-22 — Federal Register notice: VRBPAC meeting and public docket for safety/effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) manufactured by Moderna TX Inc.; meeting date stated as 2026-06-18.
• 2026-06-18 — VRBPAC meeting date stated in Federal Register notice for MFLUSIVA (Influenza Vaccine, mRNA) manufactured by Moderna TX Inc.
• 2026-07-02 — Federal Register notice: HHS termination of declaration authorizing emergency use of drugs/biological products during COVID-19 pandemic; stated effective date 2027-06-29.
• 2026-07-08 — Moderna 8-K filed (report date 2026-07-06): Board appointment (Item 5.02) and related disclosures per deterministic EDGAR enrichment.
• 2026-07-31 — Moderna 8-K filed (report date 2026-07-31): Q2 2026 financial results press release (Item 2.02) per deterministic EDGAR enrichment.
• 2026-08-05 — Form 4 sales by CEO Stephane Bancel (multiple transactions dated 2026-08-05) per deterministic EDGAR enrichment.
• 2026-08-19 — Rep. Maria Elvira Salazar purchase of MRNA ($1,001-$15,000) (and same-day sell per user-provided trade history). Same-day other reported trades include: sale of CB, purchase of MRK, sale of QCOM.
• 2026-08-21 — USAspending award modification (IDV 75D30126D21000): $82,821,809 funding-only action for FY26-27 pediatric COVID vaccines (EO 14398) listed on award page.
• 2026-08-24 — Federal Register notice: HHS request for information on categories used in federal vaccine recommendations and shared clinical decision-making.
• 2026-09-01 — Moderna 8-K filed 2026-09-01 (report date 2026-08-27): entry into material definitive agreement and financing-related items (convertible notes) per deterministic EDGAR enrichment.
• 2026-09-09 — Trade disclosure filed date for analyzed trade (MRNA purchase).

Independent analysis of public financial disclosures. Not financial or investment advice.

Sources

1. Maria Elvira Salazar | Congress.gov | Library of Congress
2. Representative Jeff Crank - Congress.gov
3. Bill Foster | Congress.gov
4. Riley M. Moore | Congress.gov
5. Ro Khanna | Congress.gov
6. S.Hrg. 118-320 — WHY DOES THE UNITED STATES PAY, BY FAR, THE HIGHEST PRICES IN THE WORLD FOR PRESCRIPTION DRUGS? 118th Congress (2023-2024)
7. EXTENSIONS OF REMARKS
8. Testimony of Professor Jeffrey Sachs
9. Text - S.181 - 118th Congress (2023-2024): No Vaccine Passports Act | Congress.gov | Library of Congress
10. S. 181
11. Compensation for COVID-19 Vaccine Injuries
12. mRNA Technologies: A Primer
13. mRNA Technologies: A Primer | Congress.gov | Library of Congress
14. Legal Issues in COVID-19 Vaccine Development and Deployment
15. Operation Warp Speed Contracts for COVID19 Vaccines and Ancillary Vaccination Materials
16. Committee Schedule for the Week of August 17 - 23, 2026 | Congress.gov | Library of Congress
17. Committee Schedule for the Week of August 31 - September 6, 2026 | Congress.gov | Library of Congress
18. NOTICE OF HEARING
19. Committee Schedule for 08/18/2026 | Congress.gov | Library of Congress
20. Committee Schedule for the Week of June 22 - 28, 2026 | Congress.gov | Library of Congress
21. House Foreign Affairs Committee | Congress.gov | Library of Congress
22. Committee Schedule for the Week of June 8 - 14, 2026 | Congress.gov | Library of Congress
23. EDGAR Filing Documents for 0001682852-26-000033
24. EDGAR Search Results
25. SEC EDGAR Submission 0001682852-26-000033
26. EDGAR Search Results
27. EDGAR Filing Documents for 0001308179-26-000080
28. mrna-20251231 - SEC.gov
29. mrna-20260331 - SEC.gov
30. mrna-20241231
31. mrna-20260630
32. Document
33. Federal Register :: Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
34. Federal Register :: Revocation of Emergency Use of Three Biological Products; Availability
35. Federal Register :: Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-2027 Southern Hemisphere Influenza Virus Vaccines
36. Federal Register :: Termination of Declaration Authorizing Emergency Use of Drug and Biological Products During the COVID-19 Pandemic
37. Federal Register :: Request for Information: Categories Used in Federal Vaccine Recommendations and the Role of Shared Clinical Decision-Making
38. IDV to MODERNA US, INC. | USAspending
39. CONTRACT to MODERNA US, INC. | USAspending
40. MODERNA US, INC. | Federal Award Recipient Profile | USAspending
41. CONTRACT to MODERNATX, INC. | USAspending
42. CONTRACT to MODERNATX, INC. | USAspending
43. Requests that the FDA revoke or suspend the approvals for the modRNA Covid-19 vaccine products of Pfizer and Moderna, and refrain from any further approving or licensing of future modRNA Covid-19 products from those companies.
44. Comment from Geoff Pain
45. Comment from Geoff Pain
46. Federal Register, Volume 91 Issue 29 (Thursday, February 12, 2026)
47. https://downloads.regulations.gov/FDA-2023-N-1553-0629/attachment_3.pdf
48. sec.gov
49. sec.gov
50. data.sec.gov
51. sec.gov

Maria Elvira Salazar · MRNA · Trading news